Thursday, 12th February 38th Lorne Cancer Conference 2026

• Leukemia-derived apelin selects endothelial niche clones to promote tumorigenesis - Leonard Zon
• Dnmt3a mutations regulate disease progression and response to treatment in acute myeloid leukaemia - Steve Lane
• Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia - Shellaina JV Gordon

Session Sponsor

• New insight into the role of nuclear receptor transcription factors in breast cancer metastasis - Jason Carroll
• Forcing inflammation to drive tumor initiation and progression - Valerie Weaver
• Acute oncogenic Myc loss induces a tissue repair program that resolves tumours - Roderik M Kortlever

Session Sponsor
 

• Mechanistic insights into how venetoclax-based therapy durably eradicates NPM1 mutated clones in acute myeloid leukaemia - Fiona C Brown
• Unravelling intra-tumor phenotypic heterogeneity by single cell analysis in colorectal cancer organoids - Sabrina J Fletcher
• Linking cell fate determination in the embryonic forebrain to Diffuse Midline Glioma - Liam M Furst
• Targeting the non-canonical NF-kB pathway using the first-in-class IKKα inhibitor SU1644: An innovative approach to combat inflammation and overcome immunosuppression in advanced prostate cancer - Giang Lam
• Targeting ICOS to improve breast cancer immunotherapy - Chamikara Liyanage
• Kap1 maintains the hormone response of the mammary gland - Michael Milevskiy

Poster Presentation Schedule (100-199):

  Odd Poster Numbers: 6:00pm - 7:00pm
  Even Poster Numbers: 7:00pm - 8:00pm

Flash Talk Posters

Mechanistic insights into how venetoclax-based therapy durably eradicates NPM1 mutated clones in acute myeloid leukaemia - Fiona C Brown (#101)

Unravelling intra-tumor phenotypic heterogeneity by single cell analysis in colorectal cancer organoids - Sabrina J Fletcher (#102)

Linking cell fate determination in the embryonic forebrain to Diffuse Midline Glioma - Liam M Furst (#103)

Targeting the non-canonical NF-kB pathway using the first-in-class IKKα inhibitor SU1644: An innovative approach to combat inflammation and overcome immunosuppression in advanced prostate cancer - Giang Lam (#104)

Targeting ICOS to improve breast cancer immunotherapy - Chamikara Liyanage (#105)

Kap1 maintains the hormone response of the mammary gland - Michael Milevskiy (#106)

Poster Presentations

• Investigating initiating factors in neuroblastoma development from prevention to therapy - Domenico Abruzzese
• Identification of checkpoint markers, cancer pathways and cancer genes in a mouse model of chronic colitis - Vasso Apostolopoulos
• Nuclear-encoded mitochondrial-associated genes as potential therapeutic targets for metastatic prostate cancer - Jasmine M Bacon
• Dual inhibition of KIF11 and BCL-XL or MCL-1 rewires mitotic cell fates and efficiently kills lung cancer cells - Amar Balihodzic
• ­Investigating the biological mechanism of diffuse hemispheric glioma in hPSC-derived 3D brain organoids - Patrick L Barry
• A Novel Zebrafish Xenotransplantation Model to Track Colorectal Cancer Metastasis. - Faiza Basheer
• CDK4/6 inhibitors and endocrine therapies induce senescence with drug- and cell line-specific vulnerabilities in ERα+ breast cancer - Lena Batoon
• Divergent patterns for genetic alterations drive pre-malignant clonal haematopoiesis in people with HIV - Kiarash Behrouzfar
• Characterization of TP53 X125 splice mutation and its role in cancer progression - Apeksha Bhandarkar
• Understanding how cancer cells adapt to changes in microenvironmental nutrient availability - Alexandra A Birrell
• Neurodevelopmental reprogramming of the cells-of-origin of diffuse midline glioma - Jakarra A Brady
• Deciphering netrin-1 implication in pancreatic cancer - Nicolas Braissand
• Targeting fibroblast growth factor (FGF)-fusions in previously untreatable cancers - Nyah C Brooks
• Beyond DNA-damage: the future of RNA-based cancer therapy for head and neck cancer - Rikki A.M. Brown
• Dysregulation of the tristetraprolin and NF-kappa B pathway contributes to estrogen receptor positive breast cancer treatment resistance. - Mark D Bunting
• Targeting subcellular JNK activity in pancreatic cancer - Antonia Cadell
• Investigating post-transcriptional responses to altered glucose availability in cancer - Nicola E Caine
• Understanding the clinical and molecular drivers of brain metastasis formation - Bethany K Campbell
• Exploring the functional and therapeutic impacts of cbl mutations in paediatric solid and brain tumours - Katherine Camper
• A whole genome CIRSPR screen to identify opportunities to overcome chemoresistance in pancreatic cancer - Nuoyi Cao
• Utilising CRISPR/Cas9 screening to uncover novel immunotherapies for targeting bone metastases in breast cancer - Thomas Chadwick
• Distinct 3D chromatin organisation underlies neuroendocrine plasticity in prostate cancer - Dayna Challis
• Utilising ex vivo models to explore the primary and metastatic microenvironment and uncover novel immune-targeted therapies.   - Hugh Chalmers
• Butyrate affected differentiation-, autophagy-, and cell cycle progression molecules in osteosarcoma cells partly via MEK/ERK signaling - Mei-Chi Chang
• Proteomic profiling of the tumor-invasive margin identifies GCHFR as a novel oncogenic regulator in hepatocellular carcinoma - Zhili Cheng
• Inhibition of oncogenic drivers induces redox stress and therapeutic resistance in non-small cell lung cancer - Kimberley Clark
• Mechanisms of oncogenic JNK signalling in metastatic triple-negative breast cancer - Misaki S Clearwater
• Spatial profiling reveals stromal-restricted immune infiltration and exclusion from tumour cores in Rhabdoid Tumours - Erin Coll
• B Cells and Tertiary Lymphoid Structures as Predictors of Prostate Cancer Outcomes - Jessica Da Gama Duarte
• Mapping the ligandable proteome of medulloblastoma for target-based drug discovery - Montana Dalziel
• Early detection of melanoma using circulating tumour-specific antibodies - Tawany T De Carvalho Gil
• Investigating the role of E. coli Nissle biofilm formation in colorectal cancer tumour colonization. - Rebekah de Nys
• A novel RNA binding protein (ZCCHC24) regulates breast cancer cell plasticity and metastasis - Shruti Deshpande
• Deciphering Mitotic and DNA Damage Pathways Driving Malignant Rhabdoid Tumour: Preclinical and Mechanistic Evaluation of Alisertib, Temozolomide, and Irinotecan Combination Therapy - Kimberly Dias
• Detecting changes in the tumour microenvironment and CAR T infiltration following chemotherapeutic priming using intravital imaging - Marija Dinevska
• Fatty acids drive ELF3-mediated neuroendocrine differentiation and progression in prostate cancer - Ez Aldeen Esawi
• Revolutionising leukaemia care: a non-invasive salivary-cytology-based screening - Falak Fazal
• A blueprint for mutation-defined hallmark vulnerabilities across human cancers - Yuchen Feng
• Repurposing the cardiac glycoside digoxin as a targeted treatment for SMARCA4-mutant ovarian cancer - Natisha R Field
• Personalized Treatment Strategies Guided by Exacta Multi-Omics Profiling in Advanced Refractory Head and Neck Squamous Cell Carcinoma (SCCHN) - Joachim Fluhrer
• Transcriptional patterns reveal heterogeneous trajectories underlying metastatic progression in prostate cancer - Yunfan Fu
• Ex Vivo Drug Efficacy in High-Risk Paediatric Cancers: A Comprehensive Analysis of the ZERO Cohort - Luke LF Fuller
• The development of a novel cell-based screening tool to reduce the impact of bowel cancer across the community. - Allegra Chajinsi Gaza
• Tuning CAR T cell response with TNFAIP3 variants - Caroline Giardina
• Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer - Katie Gordon
• A blood-based biomarker study of rare cancer patients undergoing combination immunotherapy - Eliza Grills
• Induction of interferon signalling dictates Menin inhibitor efficacy in NPM1-mutant AML - Emily Gruber
• Direct targeting of quiescent cancer stem cells - Jessica Hart
• Targeting the interplay between the Replication Stress-induced DNA Damage Response and Epigenetics for children with High-Risk Neuroblastoma - Hannah E Hartley
• Utilising Cas gene editing systems to identify non-coding lncRNA dependencies in high-risk MLL-rearranged acute myeloid leukaemia - Steven He
• Targeting the NPY/NPY1R signaling axis impairs metastasis and tissue wasting in pancreatic cancer - David Herrmann
• Stimulation of androgen receptor signalling has therapeutic efficacy in estrogen receptor positive breast tumours of no special type and of the lobular special type - Theresa E Hickey
• MoLBi: From Theatre to Therapy – Building Australia’s First Live-Biobanking Platform for Precision Immunotherapy - Gwo Yaw Ho
• CAM-on-MoLBi: A Rapid and Scalable In Ovo Platform for Translational Cancer Modelling - Gwo Yaw Ho
• Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352​ - Jacinda JH Holtsmark
• Endogenous isoform-specific CSF-1 signalling determines monocytic AML differentiation therapy response - Samin Iranfar
• ProSLeM: A Novel Computational Platform to Accelerate Synthetic Lethality-Based Treatments for Prostate Cancer - Mohammad A. Ismail
• High-throughput single-cell lentiviral integration mapping to enhance CAR T Cell safety and efficacy - Jafar S Jabbari
• Regulation of AKR1Cs’ expression of SAS oral cancer cells by areca nut and arecoline - Jiiang-Huei Jeng
• PRDM9-Mediated H3K4me3 Drives Cholesterol Metabolic Gene Expression and Chemotherapy Tolerance in Glioblastoma - George L Joun
• seg - Narasimha Raju Kalidindi
• Spatial transcriptomics reveals heterogeneity and microenvironmental shifts in breast cancer subtypes and metastatic progression - Narasimharaju Kalidindi
• A phase I/II study to assess the toxicity and preliminary efficacy of SUBA-itraconazole and dual checkpoint inhibitor cadonilimab as maintenance therapy in advanced pancreatic ductal adenocarcinoma - Bratati Karmakar
• Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma - Emma G Kempe
• Investigating the role of neutrophils in colorectal cancer metastasis using zebrafish xenotransplantation model - Ali Khalafizadeh
• CAR-extracellular vesicles (CAR-EVs) as a scalable cell-free immunotherapy for triple-negative breast cancer - Ramin Khanabdali
• A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor–immune ecosystems driving immune hot and cold phenotypes - Hani Kim
• From cells to circuits: decoding rare breast cancer ecosystems - Somi Kordafshari
• Targeting the epigenetic adaptor protein menin in multiple myeloma - Sree Kumar
• Moonlighting function of the GTP producing enzyme IMPDH2 in melanoma suppression - Gamze Kuser Abali